Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Two Case Reports of Resensitization to Previous Chemotherapy with the Novel Hypoxia-Activated Hypomethylating Anticancer Agent RRx-001 in Metastatic Colorectal Cancer Patients.

Reid T, Dad S, Korn R, Oronsky B, Knox S, Scicinski J.

Case Rep Oncol. 2014 Jan 24;7(1):79-85. doi: 10.1159/000358382. eCollection 2014 Jan.

2.

The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent.

Scicinski J, Fisher G, Carter C, Cho-Phan C, Kunz P, Ning S, Knox S, Oronsky B, Caroen S, Parker C, Fanger G, Reid T.

Redox Biol. 2015 Aug;5:422. doi: 10.1016/j.redox.2015.09.035. Epub 2015 Dec 30.

3.

Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity.

Zhao H, Ning S, Scicinski J, Oronsky B, Knox SJ, Peehl DM.

Oncotarget. 2015 Dec 22;6(41):43172-81. doi: 10.18632/oncotarget.6526.

4.

The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry.

Zhao H, Ning S, Nolley R, Scicinski J, Oronsky B, Knox SJ, Peehl DM.

Clin Epigenetics. 2017 Jan 19;9:4. doi: 10.1186/s13148-017-0312-z. eCollection 2017.

5.

RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets.

Carter CA, Oronsky BT, Caroen SZ, Scicinski JJ, Degesys A, Kim MM, Oronsky AL, Lybeck H, Cabrales P, Oronsky N, Reid T, Roswarski J, Brzezniak C.

Case Rep Oncol. 2016 Mar 11;9(1):171-6. doi: 10.1159/000444631. eCollection 2016 Jan-Apr.

6.

Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization.

Carter CA, Oronsky BT, Caroen SZ, Scicinski JJ, Cabrales P, Reid T, Degesys A, Jenkins J, Brzezniak C.

Case Rep Oncol. 2016 Jan 28;9(1):62-7. doi: 10.1159/000443725. eCollection 2016 Jan-Apr.

7.

Episensitization: therapeutic tumor resensitization by epigenetic agents: a review and reassessment.

Oronsky B, Oronsky N, Knox S, Fanger G, Scicinski J.

Anticancer Agents Med Chem. 2014;14(8):1121-7. Review.

8.

A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells.

Das DS, Ray A, Das A, Song Y, Tian Z, Oronsky B, Richardson P, Scicinski J, Chauhan D, Anderson KC.

Leukemia. 2016 Nov;30(11):2187-2197. doi: 10.1038/leu.2016.96. Epub 2016 Apr 27.

9.

Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001.

Ning S, Sekar TV, Scicinski J, Oronsky B, Peehl DM, Knox SJ, Paulmurugan R.

Oncotarget. 2015 Aug 28;6(25):21547-56.

10.

RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors.

Oronsky B, Scicinski J, Cabrales P, Minchinton A.

Clin Epigenetics. 2016 May 11;8:53. doi: 10.1186/s13148-016-0220-7. eCollection 2016.

11.

RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report.

Brzezniak C, Schmitz BA, Peterson PG, Degesys A, Oronsky BT, Scicinski JJ, Caroen SZ, Carter CA.

Case Rep Oncol. 2016 Jan 15;9(1):45-50. doi: 10.1159/000443605. eCollection 2016 Jan-Apr.

12.

Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001.

Carter CA, Schmitz B, Peterson PG, Quinn M, Degesys A, Jenkins J, Oronsky B, Scicinski J, Caroen S, Reid TR, Cabrales P, Brzezniak C.

Case Rep Oncol. 2016 Mar 10;9(1):164-70. doi: 10.1159/000444633. eCollection 2016 Jan-Apr.

13.

Rewriting the epigenetic code for tumor resensitization: a review.

Oronsky B, Oronsky N, Scicinski J, Fanger G, Lybeck M, Reid T.

Transl Oncol. 2014 Oct 24;7(5):626-31. doi: 10.1016/j.tranon.2014.08.003. eCollection 2014 Oct. Review.

14.

RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhibits glucose 6-phosphate dehydrogenase in human tumor cells.

Oronsky B, Scicinski J, Reid T, Oronsky A, Carter C, Oronsky N, Cabrales P.

Discov Med. 2016 Apr;21(116):251-65.

15.

Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors.

Raghunand N, Scicinski J, Guntle GP, Jagadish B, Mash EA, Bruckheimer E, Oronsky B, Korn RL.

Oncotarget. 2017 Jun 12. doi: 10.18632/oncotarget.18455. [Epub ahead of print]

16.
17.

A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?

Cabrales P, Scicinski J, Reid T, Kuypers F, Larkin S, Fens M, Oronsky A, Oronsky B.

Med Oncol. 2016 Jul;33(7):63. doi: 10.1007/s12032-016-0775-3. Epub 2016 May 26.

PMID:
27229330
18.

Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor.

Carter CA, Degesys A, Oronsky B, Scicinski J, Caroen SZ, Oronsky AL, Reid T, Cabrales P, Roswarski J.

Case Rep Oncol. 2015 Oct 30;8(3):461-5. doi: 10.1159/000441775. eCollection 2015 Sep-Dec.

19.

Episensitization: Defying Time's Arrow.

Oronsky BT, Oronsky AL, Lybeck M, Oronsky NC, Scicinski JJ, Carter C, Day RM, Rodriguez Orengo JF, Rodriguez-Torres M, Fanger GF, Reid TR.

Front Oncol. 2015 Jun 11;5:134. doi: 10.3389/fonc.2015.00134. eCollection 2015. Review.

20.

KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2010;10(25):1-49. Epub 2010 Dec 1.

Supplemental Content

Support Center